CLINICAL TRIALS PROFILE FOR ONC201
✉ Email this page to a colleague
Clinical Trials for ONC201
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT02038699 ↗ | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | Withdrawn | Chimerix | Phase 1/Phase 2 | ONC201 is a new potential drug that kills cancer cells but not normal cells in laboratory studies. This clinical trial will be the first evaluation of ONC201 in humans and will enroll patients with advanced cancer. This trial includes a phase I portion that will evaluate the safety of ONC201 and the recommended dose for the phase II portion. The phase II portion will evaluate the initial efficacy profile of ONC201 in select types of cancer. |
| NCT02038699 ↗ | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | Withdrawn | Oncoceutics, Inc. | Phase 1/Phase 2 | ONC201 is a new potential drug that kills cancer cells but not normal cells in laboratory studies. This clinical trial will be the first evaluation of ONC201 in humans and will enroll patients with advanced cancer. This trial includes a phase I portion that will evaluate the safety of ONC201 and the recommended dose for the phase II portion. The phase II portion will evaluate the initial efficacy profile of ONC201 in select types of cancer. |
| NCT02250781 ↗ | Oral ONC201 in Treating Patients With Advanced Solid Tumors | Completed | National Cancer Institute (NCI) | Phase 1 | This phase I trial studies the side effects and best dose of Oral ONC201 in treating patients with advanced solid tumors. Oral ONC201 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. |
| NCT02250781 ↗ | Oral ONC201 in Treating Patients With Advanced Solid Tumors | Completed | Rutgers Cancer Institute of New Jersey | Phase 1 | This phase I trial studies the side effects and best dose of Oral ONC201 in treating patients with advanced solid tumors. Oral ONC201 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. |
| NCT02250781 ↗ | Oral ONC201 in Treating Patients With Advanced Solid Tumors | Completed | Rutgers, The State University of New Jersey | Phase 1 | This phase I trial studies the side effects and best dose of Oral ONC201 in treating patients with advanced solid tumors. Oral ONC201 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. |
| NCT02324621 ↗ | Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors | Completed | National Cancer Institute (NCI) | Phase 1 | This phase I trial studies the long-term side effects of the continuation of oral ONC201 in treating patients with solid tumors that have spread to other places in the body who have previously benefited from receiving this drug. Oral ONC201 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. |
| NCT02324621 ↗ | Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors | Completed | Oncoceutics, Inc. | Phase 1 | This phase I trial studies the long-term side effects of the continuation of oral ONC201 in treating patients with solid tumors that have spread to other places in the body who have previously benefited from receiving this drug. Oral ONC201 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for ONC201
Condition Name
Clinical Trial Locations for ONC201
Trials by Country
Clinical Trial Progress for ONC201
Clinical Trial Phase
Clinical Trial Sponsors for ONC201
Sponsor Name
